RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.02 | -0.05 |
| FCF Yield | -0.31% | -5.61% | -15.59% | -27.07% |
| EV / EBITDA | -11.11 | 2.29 | 1.52 | -2.93 |
| Quality | ||||
| ROIC | -6.66% | -4.53% | -5.14% | -23.30% |
| Gross Margin | 73.50% | 71.59% | 78.74% | 54.28% |
| Cash Conversion Ratio | -0.01 | -0.34 | 1.03 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 46.21% | 52.64% | 66.19% | 59.59% |
| Free Cash Flow Growth | 90.94% | 44.54% | 51.59% | 10.67% |
| Safety | ||||
| Net Debt / EBITDA | 5.74 | -3.09 | 8.90 | 0.04 |
| Interest Coverage | 0.00 | -12.50 | -12.28 | -39.00 |
| Efficiency | ||||
| Inventory Turnover | 0.91 | 0.39 | 2.65 | 2.61 |
| Cash Conversion Cycle | 47.28 | 267.29 | 25.79 | 31.24 |